Quick Answer
Actinium Pharmaceuticals, Inc. reported Stockholders Equity of $7.83 million for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -76.1% in Stockholders Equity from 2024 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $992.0 thousand | Q1 2012: -$94.0 thousand | Q3 2012: -$104.0 thousand | Q1 2013: $550.8 thousand | Q2 2013: $1.91 million | Q3 2013: $604.3 thousand | Q1 2014: -$13.47 million | Q2 2014: $4.33 million | Q3 2014: $2.37 million | Q1 2015: $16.44 million | Q2 2015: $23.28 million | Q3 2015: $22.89 million | Q1 2016: $20.06 million | Q2 2016: $19.08 million | Q3 2016: $14.23 million | Q1 2017: $12.88 million | Q2 2017: $8.87 million | Q3 2017: $18.19 million | Q1 2018: $21.75 million | Q2 2018: $17.32 million | Q3 2018: $11.58 million | Q1 2019: $5.34 million | Q2 2019: $15.70 million | Q3 2019: $9.94 million | Q1 2020: $3.02 million | Q2 2020: $50.77 million | Q3 2020: $45.43 million | Q1 2021: $70.74 million | Q2 2021: $80.50 million | Q3 2021: $80.29 million | Q1 2022: $68.84 million | Q2 2022: $78.18 million | Q3 2022: $71.26 million | Q1 2023: $57.21 million | Q2 2023: $53.08 million | Q3 2023: $43.58 million | Q1 2024: $43.86 million | Q2 2024: $43.84 million | Q3 2024: $38.21 million | Q1 2025: $25.69 million | Q2 2025: $19.01 million | Q3 2025: $13.78 million.
- Over the full 18 years of available data (2008 to 2025), Actinium Pharmaceuticals, Inc.'s Stockholders Equity has grown by 88.4%.
- Historical annual values: Fiscal year 2025: $7.83 million | Fiscal year 2024: $32.76 million | Fiscal year 2023: $36.38 million | Fiscal year 2022: $66.48 million | Fiscal year 2021: $73.55 million | Fiscal year 2020: $61.32 million | Fiscal year 2019: $5.64 million | Fiscal year 2018: $8.81 million | Fiscal year 2017: $13.67 million | Fiscal year 2016: $18.01 million | Fiscal year 2015: $21.97 million | Fiscal year 2014: -$1.92 million | Fiscal year 2013: -$1.56 million | Fiscal year 2012: $1.15 million | Fiscal year 2011: $992.0 thousand | Fiscal year 2010: $399.1 thousand | Fiscal year 2009: $845.2 thousand | Fiscal year 2008: $4.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: